BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:As innovative drug delivery platforms beyond GalNac continue t
 o emerge and novel chemical modifications are discovered\, the potential 
 for RNAi therapeutics to treat a plethora of diseases grows. Now more tha
 n ever\, RNAi therapies hold promise to treat diseases beyond the liver a
 nd provide efficacious\, tolerable treatment options for patients.\n\nThe
  6th RNAi-Based Therapeutics Summit is returning to Boston to showcase th
 e latest delivery technologies\, data from clinically successful extra-he
 patic targeting\, cutting-edge AI tools to assist payload design\, and br
 eakthrough chemical modifications which enhance stability\, allowing for 
 precise therapeutic delivery.\n\nUniting 70+ leaders of the RNAi world\, 
 this Summit will empower experts to pioneer their RNAi candidates into cl
 inically successful therapies. Bringing together technical and strategic 
 experts from Novo Nordisk\, Alynlam\, Switch Therapeutics\, Aro Biotherap
 eutics\, Novartis\, Comanche Biopharma and more\, this meeting is a uniqu
 e gathering of RNAi's sharpest minds\, dedicated to progressing the next 
 wave of RNAi therapeutics to improve healthcare for patients in need.\n\n
 \nURLs:\nTickets: https://go.evvnt.com/2676365-2?pid=185\nBrochure: https
 ://go.evvnt.com/2676365-3?pid=185\n\nTime: 8:00 AM - 6:00 PM\n\nSpeakers:
  Adam Dinerman\, Senior Vice President and Head of Chemistry\, Manufactur
 ing and Controls\, Aro Biotherapeutics \, Ali Shah\, Co-Founder and Chief
  Executive Officer\, Tallas Biotech\, Andrew Fraley\, Partner\, Sunrise B
 ioventures\, Ashling Holland\, Director of Research and Preclinical Devel
 opment\, PepGen\, Benjamin Kreitman\, Principal\, Broadview Ventures\, Ch
 ad Miller\, Head of Research\, Nosis Biosciences\, David Jackson\, Chief 
 Executive Officer\, Ceria Therapeutics\, David Sharp\, Chief Executive Of
 ficer\, Microcures\, Eriks Rozners\, Professor\, Binghamton University Re
 search Foundation\, Glenn Kazo\, Chief Business Officer\, ARIZ Precision 
 Medicines\, Hanhua Huang\, Vice President\, Biology\, Avidity Biosciences
 \, Hunghao Chu\, Associate Director\, Benitec Ltd\, Jingfang Ju\, Profess
 or\, Stony Brook University\, Julia Alterman\, Assistant Professor\, Univ
 ersity of Massachusetts Medical School\, Lucas Siow\, Chief Executive Off
 icer and Co-Founder\, ProteinQure\, Mohammad Shadid\, Vice President - Pr
 eclinical Development\, Korro Bio\, Ruben Postel\, Chief Scientific Offic
 er and Scientific Founder\, Sapreme Technologies\, Scott Harper\, Co-foun
 der\, Armatus Bio and Principal Investigator\, Nationwide Children's Hosp
 ital\, Shanthi Ganesh\, Director - Global Nucleic Acid Therapies\, Novo N
 ordisk\, Shilpi Mahajan\, Associate Director and Head of Bioanalytics\, S
 witch Therapeutics\, Vignesh Narayan Hariharan\, Director of Biology\, Co
 manche Biopharma and Instructor\, University of Massachusetts Medical Sch
 ool\, Weimin Wang\, Founder and Chief Executive Officer\, SanegeneBio\, Y
 uanyuan Jin\, Co-founder and Chief Operating Officer\, Bound Therapeutics
 \, Zdravka Medarova\, Chief Scientific Officer\, TransCode Therapeutics\,
  Zhanna Druzina\, Senior Director\, Aro Biotherapeutics\, Zhihong Huang\,
  Associate Director\, Global Discovery Chemistry\, Novartis AG\n
DTEND:20250130T180000
DTSTAMP:20260512T231942Z
DTSTART:20250128T080000
LOCATION:W Boston\, 100\, Stuart Street\, Boston\, Massachusetts\, 02116\,
SEQUENCE:0
SUMMARY:As innovative drug delivery platforms beyond GalNac continue to em
 erge and novel chemical modifications are discovered\, the potential for 
 RNAi ther...
UID:fcb17036-a223-40c3-a922-7878bf0b2bb4
END:VEVENT
END:VCALENDAR